"After the Wei Zexi incident, the domestic cellular immunotherapy research process has almost stalled." Ling Feng, a member of the National Committee of the Chinese People's Political Consultative Conference and director of neurosurgery at Xuanwu Hospital, told the China Youth Daily reporter.

The Wei Zexi incident should not be the end sign of cellular immunotherapy. In 2016, the "Wei Zexi incident" received much attention. The deceased Wei Zexi suffered from synovial sarcoma during his lifetime and received biological immunotherapy (DC-CIK cell therapy) at the Second Hospital of the Beijing Armed Police Corps.

Looking back on the Wei Zexi incident nearly a year later, Ling Feng pointed out, “This therapy may not be suitable for him, or the doctor promised him too much, which gave him too much hope and spent so much money. In the end, it did not achieve the desired effect, which made people and money empty. We cannot evaluate the immune cell therapy technology of the hospital, but we can see that the whole world is studying cellular immunotherapy, which has been recognized as a successor to surgery and chemotherapy. , The fourth major anti-tumor therapy after radiotherapy.” Ling Feng introduced, one of the main principles of “cellular immunotherapy” is to mobilize the patient’s own resistance and combat power to resist tumor cells, instead of killing the body like chemotherapy and radiotherapy. Cause a lot of damage. In theory, this is one of the most promising development directions for tumor therapy and one of the current research hotspots in the field of tumor therapy.

"There is an incident, it is right to consider and review seriously, it shows that the government has a good ability to respond." But Ling Feng pointed out that now the nationwide cellular immune research work is in a stagnant or slow state, in fact, many patients receive this therapy It's really effective. "A few days ago, "New England Journal" published a case of intracranial glioma. Through cellular immunotherapy, the tumor was significantly reduced. There are also a group of scientists and medical workers in my country who are conducting pre-clinical research with a serious scientific attitude. And we have achieved gratifying results in clinical research. We can’t'one size fits all','death as soon as you catch it, and mess up as soon as you put it away' is too'fearful'. The government should be responsible, and good technology must be released, fake and inferior Severe punishment," she said.

Speaking of the current core issues, Ling Feng believes that it should be how the government regulates management: First, it should be clear as soon as possible to which institution the medical technology should be registered, approved or filed; when the competent government department will begin to accept and approve; Whether the immunotherapy technology is submitted for approval and supervision completely according to the medicine; how to learn from the experience of international supervision and conform to my country's national conditions. "In a situation where major global pharmaceutical companies are investing heavily in research and development, new technologies or products of cellular immunotherapy are constantly entering clinical research or listing, in the context of the CPC Central Committee and the State Council encouraging'double innovation' and the transformation of China's economic structure, Many scientific and technological workers and scientific and technological enterprises in the field of biotechnology in China have developed new technologies and new products, but they are waiting to cross this single-plank bridge and cannot be converted into productivity as soon as possible. We are pleased to see that in December 2016, the National Food and Drug The Center for Drug Evaluation of the General Administration of Supervision and Administration issued the "Technical Guidelines for Research and Evaluation of Cell Products" (draft for comments), but everyone is looking forward to the launch of the review and registration in this field," she said.